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framework for studying access to health care. ED visits were classified into avoid-
able or not using the New York University algorithm. Patient complexity was mea-
sured using the Chronic Illness Intensity Index (CI3), an index used to measure
need of case management intensity. We performed logistic regression models to
test for significant association between AEDV, and population at risk and health
care delivery characteristics. RESULTS: We found that 69% (179) of our population
had an ED visits during 2008-2009. Of these visits, 60% were classified as AEDV. The
analysis showed that women were 33% less likely to have an AEDV per month. Age
was negatively associated, with younger patients being more likely to have AEDV.
More complex patients were 6.6% more likely to have an AEDV. For every extra
physician a patient visited, the probability of having an AEDV per month increased
by 2.4%, however this was not significant (p 0.06) at 95% confidence interval.
CONCLUSIONS: Among high cost, high risk Medicaid patients there are certain
patient characteristics that can allow us to identify those at higher risk of having an
AEDV. This information could be use to identify groups that would benefit from
interventions to reduce ED utilization.
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OBJECTIVES: Formal systems of health technology appraisal (HTA) can directly
inform resource allocation in healthcare systems and have contributed to the eq-
uitable and efficient allocation of such resources. To engender and maintain sup-
port from a wide range of stakeholders it is important that HTA systems are seen a
socially just, particularly in the face of contentious decisions. Effective appeals
processes, internal or judicial, can have an important role in meeting this goal,
enabling stakeholders to directly question the evidence considered, its interpreta-
tion, and the decision making process. We conducted an empirical review of the
results of all appeals made to the National Institute for Clinical Excellence (NICE)
between the years 2000 and 2010, and consider whether NICE fulfills these
requirements.METHODS:A retrospective review of all completed NICE technology
appraisals published between March 2000 and October 2010 was conducted. Each
technology appraisal was investigated for appeals. Published appeals were then
categorized by appeal substance, stakeholder, and outcome. The results were pre-
sented as absolute numbers and proportions of overall responses. RESULTS: In this
study 29% of appraisals resulted in a published appeal of which 41% were upheld.
The most common ground for an appeal, 59% of total, was perversity of the deci-
sion, the main substance for those appeals was misinterpretation of the clinical or
cost-effectiveness evidence. By proportion of appeals upheld the most successful
appeal point was that the HTA did not meet the scope or was deemed to be ineq-
uitable. Appeals involving a professional body or patient group were also more
likely to be successful. CONCLUSIONS: Examination of appeals to NICE would sug-
gest that a socially just and effective appeals process is in place. Decisions are
reversible and transparent and stakeholders can both participate in and question
the decision process.
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OBJECTIVES: Over the last decade, specialist pharmacists across Europe have seen
an emergent role in many areas of the healthcare pathway. This research exam-
ined four key domains - clinical, policy, education and research - of influence of
specialist pharmacists with goal of understanding how they can impact market
access of drugs.METHODS: Structured interviews with 25 specialist oncology phar-
macists from EU5 exploring various aspects within the four identified domains of
influence. RESULTS: A selection of the most important roles of the specialist phar-
macist by domain is presented below: Clinical: 1) Coordinate safe and timely ad-
ministration of drugs and supportive treatment; 2) Coordinate outpatient support-
ive care focusing on management of symptoms; and 3) Help develop treatment
guidelines to ensure optimal use of supportive care medications. Policy: 1) Provide
formulary review for new drugs, and 2) Facilitate reimbursement for a more effi-
cient practice. Education: 1) Educate patients and members of the HC team about
drugs and their expected side effects and management, and 2) Educate members of
the public about prevention strategies and recommendation for screening and
early detection. Research: 1) Conduct internal treatment protocol audits to opti-
mise patient care pathway, and 2) Participate in institutional review board for
approval of clinical trials as well as scientific review and monitoring committees.
CONCLUSIONS: A cornerstone of market access is identification of important
stakeholders within a health care economy with the goal of understanding the
roles they play in the care pathway. The specialist pharmacist is an often over-
looked, but increasingly important stakeholder in the European health care sys-
tem. The multitude of roles played by the specialist pharmacist is in itself evidence
of increasing importance of the role. Pharmaceutical companies will need to en-
gage more closely with specialist pharmacists to ensure better patient outcomes
through appropriate use of drugs leading ultimately to increased market access.
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OBJECTIVES: The Committee for the Assessment of Hospital Drugs, led by the
Catalan Agency of Health Information Assessment and Quality, has provided evi-
dence-based information to regional health care decision-makers in Catalonia
about the added therapeutic value (ATV) of centralized approved drugs fit into the
orphan or advanced therapies category or have conditional approval or were ap-
proved in exceptional circumstances. This study describes the committee’s activity
since its creation.METHODS: Systematic reviews of efficacy, safety and cost-effec-
tiveness are conducted upon request from the Pharmacy Directorate and results
are appraised by expert panels. RESULTS: A total of 22 drugs (24 indications) for an
estimated population of 1.100 patients have been assessed. Most drugs were
granted approval for two major therapeutic areas: onco/hematological (41%) and
metabolic diseases (32%). Orphan designation had been given to 70% of all indica-
tions. Only 8 indications were given positive opinion based on 2 clinical trials. Most
pivotal studies were randomized phase III trials and were considered to have mod-
erate (63%) to high (25%) risk of bias. Placebo was the most frequent comparator in
controlled studies but was only considered appropriate in half. Primary endpoint
was a surrogate/intermediate endpoint in 94% of studies. Relevance of efficacy
results was difficult to interpret due to design flaws, small samples and short-term
follow-ups. Scarce or no data on effectiveness was available. Information on com-
parative safety was also scant and limited by short-term follow-ups. At time of
assessment cost-effectiveness data was missing in 66% of the indications. Re-
ported base-case incremental cost-effectiveness ratios from manufacturers ranged
from 16.000-565.000£/QALY. CONCLUSIONS: Defining ATV of new entities at the
time of introduction proved a challenge because of low quality studies and lack of
information about relative effectiveness. Registers and/or risk-sharing schemes
may be an alternative to gather more information new about drugs and establish
their real ATV while facilitating access.
Health Care Use & Policy Studies – Health Care Costs & Management
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OBJECTIVES: Urban green spaces (UGS) are thought to impact on health and well-
being. Cost-effectiveness analysis (CEA) can help to determine if provision or in-
terventional use of urban green spaces can contribute to population health in a cost
effective manner. This mapping review aims to characterise the study designs,
independent variables, outcomes and outcome measures reported in the
literature. METHODS: Key health and medical databases were searched. Studies of
any design (except reviews) which attempted to value the health and wellbeing
effects of UGS were included. One reviewer selected studies with a proportion
checked by a second and third reviewer. Data were extracted from abstracts using
a standardised form. Data were coded using a grounded theory approach and syn-
thesised in graphical and tabular form. RESULTS: A total of 189 citations were
included. The most common study design was cross sectional regression analyses;
there were only three randomised controlled trials. Many putative independent
variables were identified, including psychological, socio-economic, environmental
and interventional variables. Settings and populations also varied. Outcomes
coded as health behaviours included physical activity, visit frequency, nutrition
and social interaction; those coded as health outcomes included general health,
mental health, quality of life, wellbeing, mortality, obesity and cardiovascular in-
dices amongst others. Outcome measures were generally not compatible with CEA.
Amongst 61 economic studies, the most common study type was hedonic pricing.
Only one limited CEA analysis was identified. CONCLUSIONS: Few randomised
studies have been performed and available evidence would not allow a traditional
CEA. Existing trials have limited external validity according to criteria normally
used in health contexts. Current evidence may better lend itself to logic modelling,
as the causal pathways are long and complex and green space is likely to act at both
the individual and population level. To aid CEA, future research should carefully
choose study design, outcomes and outcome measures.
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OBJECTIVES: We estimated increases in medical expenditures due to medication
nonadherence and potential savings of increasing adherence for members of a
prescription-drug benefit plan taking medications in four drug therapy classes
(TCs).METHODS:We used data from the Medical Expenditure Panel Survey (MEPS)
to estimate functional relationships between adherence and resource utilization
for patients taking medications in four TCs. Resource use included all-cause and
disease-specific annual hospitalizations and emergency room (ER) visits. TCs in-
cluded depression, diabetes, high blood cholesterol (cholesterol), and high blood
pressure or heart disease (heart). Adherence was estimated using the medication
possession ratio (MPR). MPR less than 80% was considered nonadherence. Average
medication expenditures, by TC, was obtained from a large prescription-drug da-
tabase. Expenditures per hospitalization and ER visit were estimated from MEPS.
Unit costs and functional relationships between adherence and resource use were
applied to estimate annual resource use and medication expenditure. Increased
expenditures due to nonadherence were estimated for nonadherent patients ver-
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sus those with 80% adherence. Total expenditures considered expenditures from
inpatient admissions, ER visits, and medications. Potential savings was defined as
reduction in total expenditures due to increasing adherence. RESULTS: Nonadher-
ence resulted in increased all-cause total expenditures in diabetes, cholesterol, and
heart by $240 million (M), $150M, and $47M, respectively. Increasing adherence by
2% reduced increases in all-cause expenditure by 11% to 21%. Nonadherence re-
sulted in increased disease-specific hospitalization and ER visit expenditure for
depression ($6M), diabetes ($44M), and cholesterol ($5M). However, increases in the
disease-specific hospitalization and ER expenditures were offset by lower medica-
tion expenditure, thus resulting in overall lower disease-specific expenditure
among the nonadherent patients. Overall, increases in medication adherence re-
sulted in savings in all-cause expenditure but not in disease-specific expenditure.
CONCLUSIONS: Medication nonadherence can be costly to payers. Increasing ad-
herence even by small amounts may result in significant savings.
PHP60
DRUG-RELATED MORBIDITY – MODELING THE COST-OF-ILLNESS IN SWEDEN
USING PHARMACISTS’ OPINION
Gyllensten H1, Hakkarainen KM1, Jönsson AK2, Andersson Sundell K1, Hägg S2,
Rehnberg C3, Carlsten A1
1Nordic School of Public Health, Gothenburg, Västra Götaland, Sweden, 2Linköping University,
and the County Council of Östergötland, Linköping, Östergötland, Sweden, 3Karolinska Institutet,
Stockholm, Stockholm, Sweden
OBJECTIVES: The aim of this study was to estimate prevalence and preventability
of drug-related morbidity in Sweden based on pharmacists’ expert opinion. Fur-
thermore, the aim was to estimate the cost-of-illness (COI) of drug-related
morbidity.METHODS: Probabilities of therapeutic outcomes of medication therapy
were estimated by an expert panel of pharmacists (N29) using a two-round del-
phi-methodology and a conceptual model of drug-related morbidity based on a
decision tree. We used an American conceptual model adjusted to the Swedish
context. In the model, drug-related morbidity included new medical problems (ad-
verse drug reactions, drug dependence and intoxications by overdose) and thera-
peutic failures (insufficient effects of medicines and morbidity due to untreated
indication). The cost-of-illness analysis included all direct costs applying a health
care perspective, using national statistics on costs. RESULTS: The expert panel
estimated that 6114% (mean  SD) of all patients visiting health care suffered
from drug-related morbidity, of which 298% suffered from new medical prob-
lems, 176% from therapeutic failures, and 147% from a combination of both
types. Of patients with drug-related morbidity, 4418% suffered from preventable
drug-related morbidity. Participants estimated that 7-39% of patients with drug-
related morbidity do not require further attention, but a majority requires health
care resources due to the drug-related morbidity. The direct costs were calculated
to EUR 575 (2009 value) per patient, which corresponds to an annual cost of EUR 4
billion to the Swedish health care system. The largest component in the COI of
drug-related morbidity was hospitalizations, with 50% of the total cost. Advanced
specialist care represented 20%, and prolonged hospital stay 11% of the resulting
costs. CONCLUSIONS: Drug-related morbidity is perceived frequent and often pre-
ventable. The estimated health care costs for this morbidity are extensive, and
comparable in magnitude to the cost of dispensed medicines in Sweden. Effective
and cost-efficient methods to reduce the drug-related morbidity are needed.
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OBJECTIVES: Controlling pharmaceutical costs has been the subject of research
and analysis in many studies in health economics which have shown that the
chronic conditions of patients are an important factor. The present work models
pharmaceutical expenditure by different health districts and gender according to
the characteristics of chronic conditions. METHODS: An analysis was made of
pharmaceutical expenditure between November 2008 and October 2009 of four
health districts of the Autonomous Valencian Government, with an assigned pop-
ulation of 625,246. Those who had followed treatments for chronic conditions were
identified associating the pharmaceutical groups (ATC codes) with 24 chronic con-
ditions, according to electronic prescription data. Multivariate regression analysis
was used, where the pharmaceutical expenditure in primary health care was ex-
plained through the gender, pharmaceutical co-payment status and the number of
chronic conditions, varying from 1 to 8 or more. RESULTS: The percentage of pa-
tients with chronic conditions obtained was of 27.82%, who constituted 58.2% of
the total pharmaceutical cost. Pharmaceutical co-payment status was excluded
from the model due to its high correlation with the number of chronic conditions.
The goodness of fit obtained for explaining the expenditure of the whole popula-
tion was of 57.2%. The models obtained by health district explained between 56.5
and 60.6%, improving in the models obtained solely for the male population, where
they reached 62% for one of the districts studied. Men’s pharmaceutical expendi-
ture was the 68.31% of women’s. However, the number of chronic conditions has a
greater impact on men’s pharmaceutical expenditure than women’s.
CONCLUSIONS: Although for the whole population the proposed model explained
the 57.2% of the pharmaceutical expenditure, differences can be observed between
models obtained for each district or for gender. These models may be more suitable
than the general model for cost management and establishing incentives for gen-
eral practitioners in the different districts.
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OBJECTIVES: Taipei Medical University Shuang-Ho Hospital officially opened on
July 1, 2008. Due to limited revenue during the initial period, hospital emphasized
more on cost control. With the great demand of medication from the growing
numbers of outpatients visits and inpatients, pharmacy aim to establish an opti-
mal purchase model to minimize drug inventory management cost. METHODS:
Economic Order Quantity (EOQ) model were applied to find out the best quantity
and frequency on medication purchase order. We analyzed the high-cost medica-
tions in which the top 50% of cumulative drug cost in year 2010, and intravenous
antineoplastic drugs were excluded. RESULTS: The study evaluate drug cost, labor
cost and inventory cost. Forty-six high-cost medications were selected to deter-
mine EOQ model in this study. The optimal frequency to order each drug estimated
by EOQ model was three to ten times per month. The estimated cost of inventory
management reduced substantially when order more frequently within 10 times a
month. However, after considering the practicability in real practice, the order
frequency was adjusted to one to four times per month. The best estimated quan-
tity for each drug was also adjusted by previous fluctuation of purchase orders
during 2010. Therefore, the estimated inventory management cost in year 2011
could reduce 500,000 to 700,000 NTD CONCLUSIONS: Our inventory management
currently purchase drug twice a month. In order to optimize inventory turnover
rate, without increasing pharmacists work loading and management cost, we rec-
ommend adjusting quantity and frequency of ordering medication based on our
finding to achieve the minimal and rational cost on inventory management.
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Due to the financial crisis, Greece was forced by the International Monetary Fund
and the European Community (Troika) to implement cost containment measures
in the health care sector. OBJECTIVES: The objective of the study is to present the
measures taken in order to control and reduce the pharmaceutical expenditure in
all NHS hospitals and evaluate the respective savings emerging in 2010.METHODS:
The data derive from the Ministry of Health and Social Solidarity (MoH) database,
covering all NHS & IKA hospitals operating in the 7 Regional Health Authorities
(RHA) of Greece. Data compare the NHS hospital pharmaceutical expenditure be-
tween 2009 and 2010. RESULTS: Numerous cost-containment measures have been
gradually implemented in all NHS hospitals according to the IMF and MoH guid-
ance, targeting at: 1)creation of NHS database network (esy.net); 2)transfer of the
pharmaceutical pricing regulation from the Ministry of commerce to the MoH;
3)unification of the NHS electronic coding system, for ordering and prescribing of
pharmaceuticals; 4)hospital packsize; 5)electronic patients files; and 6)increase in
the use/penetration of generics & off patent medicines. Although the above mea-
sures are still not fully implemented, they reduced hospital pharmaceutical expen-
diture by 10.51%, from €1.466 million in 2009 to €1.312 million in 2010. At regional
level, savings ranged from 8% in the 2nd RHA (covering Pireaus & islands) up to 16%
in 6th RHA (Peloponnese & Western Greece). Moreover, in the 1st RHA covering the
highest share of NHS hospitals of pharmaceutical expenditure was reduced by 15%.
CONCLUSIONS: The new cost containment measures implemented in Greek NHS
hospitals started presenting results by fulfilling the savings imposed by IMF &
Troika). The same picture is presented in the overall HC sector, hospitals & social
security funds. The goal of €350million savings by the NHS hospitals seems to be
able to be achieved by the end of 2011.
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OBJECTIVES: In Switzerland, emergency care has no gatekeeping system and
emergency wards are increasingly overcrowded by walk-in patients. This leads to
inefficient use of spezialised resources. Treatment costs are paid by public sources
and, beyond some co-payment, reimbursed by health care insurances via tariffs.
Given the problems above, a public hospital (Stadtspital Waid; Zurich; catchment
population 180’000 people) reorganised its emergency service in 2008. A nurse led
triage system and a General Practitioner-led emergency service was implemented
beside the conventional emergency ward. To better understand the impact, we
assessed quality of service provision and total treatment costs. METHODS: From
the public payer perspective, we compared annual treatment costs for ambulatory
emergency care in 2007 with 2009. In a pre-post study, all consecutive ambulatory
emergency patients were included during one month in each year. Treatment costs
(CHF) were calculated (e.g. nursing time multiplied with wages) and extrapolated to
one year. Waiting times and patient satisfaction were used as indicators for service
quality. Clinical outcome was not directly measured. RESULTS: The annual num-
ber of ambulatory patients increased from n10’440 (2007) to n16’035 (2009).
Service provision improved with reduced waiting times (mean: 120 min vs. 60 min),
persistently high patient satisfaction and more efficient resource use (additional
diagnostic testing: 71% vs. 56%). Comparison of the annual local budget spent for
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